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Abstract
The ABCC9 gene and its polypeptide product, SUR2, are increasingly implicated in human 
neurologic disease, including prevalent diseases of the aged brain. SUR2 proteins are a component 
of the ATP-sensitive potassium (“KATP”) channel, a metabolic sensor for stress and/or hypoxia 
that has been shown to change in aging. The KATP channel also helps regulate the neurovascular 
unit. Most brain cell types express SUR2, including neurons, astrocytes, oligodendrocytes, 
microglia, vascular smooth muscle, pericytes, and endothelial cells. Thus it is not surprising that 
ABCC9 gene variants are associated with risk for human brain diseases. For example, Cantu 
syndrome is a result of ABCC9 mutations; we discuss neurologic manifestations of this genetic 
syndrome. More common brain disorders linked to ABCC9 gene variants include hippocampal 
sclerosis of aging (HS-Aging), sleep disorders, and depression. HS-Aging is a prevalent 
neurological disease with pathologic features of both neurodegenerative (aberrant TDP-43) and 
cerebrovascular (arteriolosclerosis) disease. As to potential therapeutic intervention, the human 
pharmacopeia features both SUR2 agonists and antagonists, so ABCC9/SUR2 may provide a 
“druggable target”, relevant perhaps to both HS-Aging and Alzheimer’s disease. We conclude that 
more work is required to better understand the roles of ABCC9/SUR2 in the human brain during 
health and disease conditions.
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Introduction
Hippocampal sclerosis of aging (HS-Aging) (Nelson, et al., 2014,Nelson, et al., 2015) is a 
common age related brain disorder, characterized by cognitive deterioration that mimics 
Alzheimer disease (AD) clinically but has a different brain histopathology, a distinctive 
genetic predisposition, and a later age range for maximal risk (Brenowitz, et al., 
2014,Murray, et al., 2014,Nelson, et al., 2013,Zarow, et al., 2012). Although HS-Aging and 
AD are challenging to distinguish in a living patient (Brenowitz, et al., 2014,Pao, et al., 
2011,Yu, et al., 2015), it is likely that each disease will require different strategies for 
prevention or treatment. The underlying pathogenesis of HS-Aging is unknown currently, 
but there are indications that the ABCC9 gene may play a key role. This review will 
summarize what is known about the ABCC9 gene in the human brain and describe our 
hypothesis linking ABCC9 with HS-Aging. We consider the relevant genetic and 
evolutionary biologic literature, along with current understanding of ABCC9 function and 
how the gene may be related to other human diseases.
ABCC genetic phylogeny and the role of ABCC9 paralogs in human 
diseases
ABCC9 (ATP-binding cassette, sub-family C member 9) gene products are referred to as 
sulfonylurea receptor 2 (SUR2) proteins. The term “sulfonylurea receptor” derives from the 
fact that sulfonylurea drugs bind to and block protein activity. Thus we employ established 
terminology referring to the ABCC9 gene, which serves as the template for SUR2 mRNA 
and SUR2 protein (Nichols, et al., 2013,Shi, et al., 2012). SUR2 regulates potassium (K+) 
channels in plasma membrane and intracellular organelles (Fig. 1), and other aspects of 
genomic regulation and protein function are described in greater detail below.
Themes emerge to shed light on human ABCC9 from studies in other species. The “ABC” 
gene cluster encode large transmembrane proteins and members of this gene family have 
been identified from every biologic phylum including bacteria (Cui and Davidson, 
2011,Igarashi, et al., 2004). Each gene encodes polypeptides with the same basic unit being 
one or two nucleotide binding domains (NBD), each associated with a conserved 
transmembrane domain (TMD) (Igarashi, et al., 2004). Historically, the ABCC sub-cluster 
was termed “multidrug-resistant associated proteins” because of the ability of some ABCC 
proteins to extrude drugs and toxins from cells (Bouige, et al., 2002,S.F. Zhou, et al., 2008). 
The “SUR”-subclass of ABCC genes contain a pair of TMD-NBD domains, with a unique 
third TMD (TMD0, Fig. 2). SUR genes encode a subtype of K+ channel regulators, and K+ 
channels are the most widely expressed ion channel among biologic species (Littleton and 
Ganetzky, 2000) with a broad range of functions.
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Absent in plants and fungi, direct SUR gene orthologs are numerous in invertebrate species 
(Frey, et al., 1998,Sturm, et al., 2009), and these genes provide clues about the 
evolutionarily ancient SUR gene functions. In D. melanogaster, for example, a direct SUR 
ortholog was identified (Dermauw and Van Leeuwen, 2014). This “dSUR” gene has been 
implicated in aging, metabolism (including lipid processing and insulin signaling), sleep, 
and survival after infection or stress (Akasaka, et al., 2006,Allebrandt, et al., 2013,Croker, et 
al., 2007,Nasonkin, et al., 1999,Ocorr, et al., 2007). There are intriguing results that indicate 
that dSUR plays a role in aging; the gene is important in the cardiac hypoxic stress response 
but downregulated in aging (Akasaka, et al., 2006,Nishimura, et al., 2011,Ocorr, et al., 
2007). The spider T. urticae harbors the largest number of ABCC subfamily member genes 
of any animal known, including a SUR gene (Dermauw, et al., 2013). The expansive “burst” 
of ABCC genes in this agricultural pest species may help explain this species’ ability to 
resist pesticidal strategies (Dermauw, et al., 2013). By contrast, some invertebrate species 
(silkworms) appear to lack direct SUR homologs (Xie, et al., 2012).
Among vertebrate species, two SUR-type paralogs are relatively well conserved -- termed 
ABCC8/SUR1 and ABCC9/SUR2 in humans (Fig. 1). Protein sequence homology between 
human and zebrafish SUR2 is 79–80% (Fig. 3). It is clear from genetic manipulation that 
these SUR genes play phylogenetically durable roles in multiple organs and tissues, 
including stress response, metabolism, and regulation of blood vessel function (Babenko, et 
al., 1998,Bryan, et al., 2007,Flatt, et al., 1994,Seino, et al., 2000,Seino and Miki, 
2003,Solbach, et al., 2006). Interestingly, there have been shown to be age-dependent 
changes in KATP channels in a number of species including humans (Bao, et al., 2013,Du, 
et al., 2013,Kawano, et al., 2010,Toyoda, et al., 1997,Tricarico, et al., 1997,Vajapey, et al., 
2014). As discussed below, the molecular basis of their function is understood to be 
primarily as K+ channel regulators(Nichols, 2006), but there are multiple studies suggesting 
additional actions that may contribute to the wide physiological impact. ABCC8/SUR1 
function is best understood in its role in the vertebrate pancreas and central neuronal tissue, 
as a controller of insulin secretion and neuronal excitability. In non-mammalian vertebrates, 
the ABCC9/SUR2 orthologs (sur2), in both goldfish (Carassius auratus), and in yellowtail 
flounder (Limanda ferruginea), are reported to participate in those species’ cardiac hypoxic 
stress response (Cameron, et al., 2013,MacCormack and Driedzic, 2002). Some 
neurobiological functions have also been implicated for SUR2 in non-mammalian 
vertebrates. For example, experiments in frogs showed that SUR modifying drugs impacted 
the neuromuscular junction presynaptically (Salgado, et al., 1993). In chickens, an opioid 
signaling cascade includes SUR2 modulation (Tu, et al., 2008).
Additional clues about potential physiological and pathogenetic roles are provided by 
ABCC9 paralogs in the human genome, presumed to have evolved from a common ancestral 
gene, that are associated with altered risk for human diseases. For example, mutations of 
ABCC7/CFTR cause cystic fibrosis, the most common fatal genetic disease in Americans 
(Riordan, et al., 1989). In comparison to ABCC7, ABCC8/SUR1 is far more homologous to 
ABCC9/SUR2 (Fig. 3). ABCC8 is considered to be more highly expressed in the human 
brain than ABCC9 (Shi, et al., 2005), and ABCC8/SUR1 has been implicated in 
neuropathologic processes (Jiang, et al., 2007,Mehta, et al., 2013,Simard, et al., 
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2008a,Simard, et al., 2008b,Simard, et al., 2012,Tosun, et al., 2013). Mutations in ABCC8 
are associated with congenital hyperinsulinism and diabetes (Bonfanti, et al., 2015,Bryan, et 
al., 2007,Efferth, 2003,Haghverdizadeh, et al., 2014,Remedi and Nichols, 2009,Smith, et al., 
2007). In the latter case, more severe mutations are associated with a complex syndrome 
(Developmental delay, Epilepsy and Neonatal diabetes, DEND), in which CNS excitability 
is aberrant, as a result of hyperactivity of the SUR1-regulated KATP channel activity. That 
the same disease can result both from mutations in ABCC8 and in the associated K+ channel 
pore gene, KCNJ11/Kir6.2, located nearby in Chromosome 11p (Fig. 1)(Busiah, et al., 
2013,Florez, et al., 2004,Gloyn, et al., 2003,Koster, et al., 2008,Laukkanen, et al., 
2004,Nielsen, et al., 2003,van Dam, et al., 2005) underscoring the complex 
interconnectedness of the SUR genes with their K+ channels (Bonfanti, et al., 2015,Inoue, et 
al., 1997,Olson and Terzic, 2010).
We can summarize three themes relevant to human ABCC9 functions, based on studies of 
other genes and organisms. First, bona fide SUR genes expressed in invertebrates have been 
associated with diverse functions including resistance to various stressors and neurotoxins. 
Second, multiple genes of the ABCC cluster, that share characteristics with ABCC9, are 
associated with human disease conditions including neuropathological outcomes. And 
finally, among vertebrates, 2 SUR and 2 Kir proteins are strongly conserved, widely 
expressed, and closely interconnected in function.
ABCC9/SUR2 function: biochemistry and physiology
SUR proteins provide regulatory subunits of KATP channels which respond to metabolic 
perturbations (Minami, et al., 2004,Nichols, 2006). A complex interplay has been 
characterized between ATP inhibition, via an interaction with the pore-forming subunit, and 
ADP-dependent activation, via interaction with the NBDs of the SUR subunit. These 
activities result in channel sensitivity to local metabolic state -- opening when the ratio of 
ATP/ADP is low. By blocking or enhancing the ADP (activation) effect, the compendium of 
pharmacologic agonists and antagonists, many of which are used extensively in humans (de 
Weille, et al., 1989,Isomoto and Kurachi, 1997,Jackson and Bressler, 1981a,Jackson and 
Bressler, 1981b,Melander, et al., 1989,Misler and Giebisch, 1992,Stowers and Borthwick, 
1977), interact directly with the SUR subunits.
Biochemical and biophysical studies indicate that the functional KATP channel is an octamer 
consisting of four pore-forming Kir6 proteins, each associated with one SUR subunit 
(Clement, et al., 1997,Shyng and Nichols, 1997) . The association is necessary for the 
complex to traffic to the cell membrane: both SUR and Kir6 proteins contain polybasic 
sequences that act as endoplasmic reticulium retention signals, which are effectively masked 
when the two proteins are associated (de Araujo, et al., 2011,Lodwick, et al., 2014,Nichols, 
2006,Park, et al., 2008,Park and Terzic, 2010). The genes that encode these proteins are 
shown in Fig. 1, and the understood geometric dispositions of the various proteins depicted 
in cartoon form. Although biochemical regulation of the KATP channel function is 
incompletely understood, particularly in the brain, a number of post-translational 
modifications have been reported. For example, SUR2 is affected directly by glycosylation, 
sulfhydration, and protein kinase A phosphorylation (Gade, et al., 2013,Gao, et al., 
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2014,Kang, et al., 2014,Light, 1996). The KATP channel is also regulated via separate 
phosphorylation event(s) in the Kir6.x channels (Edwards, et al., 2009,Ko, et al., 
2008,Sanada and Kitakaze, 2004,Sun, et al., 2008), again showing complex functional 
interdependence of these proteins.
RNA splicing, producing alternative SUR2 mRNA transcripts, is a conspicuous feature of 
ABCC9/SUR2 regulation (Chutkow, et al., 1999,Shi, et al., 2005,Ye, et al., 2009). Reported 
ABCC9-derived transcripts are presented in Fig. 4. Most prior studies have focused on two 
important SUR2 splice variants, which are termed SUR2A and SUR2B. These transcripts are 
generated through differential splicing of two ABCC9 exons which encode the polypeptides’ 
carboxy terminal portions (Chutkow, et al., 1996,Davis-Taber, et al., 2000,Inagaki, et al., 
1996,Isomoto, et al., 1996). SUR2A has been reported to show relatively high expression in 
cardiac and skeletal muscle cells, whereas SUR2B is more broadly expressed including in 
smooth muscle cells and brain (Chutkow, et al., 1996,Davis-Taber, et al., 2000,Isomoto, et 
al., 1996,Ploug, et al., 2010,Shi, et al., 2005).
A poorly understood RNA splicing event skips 25 internal ABCC9 exons to produce a 
smaller gene product that is trafficked to the internal mitochondrial membrane (Ye, et al., 
2009). This “mitoSUR” protein variant (~55kDa) is approximately one third the size of 
“full-length” SUR2 (Figs. 2B, 4G) and the pharmacologic properties are profoundly 
different from the larger daughter proteins of ABCC9 (Liu, et al., 2001) . The mitoSUR has 
been described in many contexts including mammalian brain (Aggarwal, et al., 
2010,Aggarwal, et al., 2013,Fahrenbach, et al., 2014,Lacza, et al., 2003,Maack, et al., 2009). 
Genetic lesions in ABCC9 may also differentially affect the expression/splicing, or function, 
of mitoSUR, SUR2A, and/or SUR2B depending on sequence location. There are other SUR2 
transcripts for which the protein products’ functions are essentially unknown (Fig. 4), and 
these observations underscore the necessity for obtaining more basic information about 
ABCC9.
Experimental studies have elucidated numerous functions for KATP channels, varying by 
cell-specific, developmental, metabolic, and stress related factors. Here we show schematic 
diagrams depicting current hypotheses that may be relevant to human brain KATP channels 
(Figs 5–7). Each figure represents a different paradigm where SUR2 is involved in response 
to different stimuli and to changes in environment.
In many different cell types, SUR2 may compensate for stress and/or hypoxia by changing 
membrane hyperpolarization toward a voltage state that attenuates local intracellular Ca++ 
levels (Fig. 5). Much of the published experimental work to date has focused on cardiac 
myocytes, where KATP channels are involved in the important paradigm of “ischemic 
preconditioning” (Rana, et al., 2015,Sanada and Kitakaze, 2004), a term that refers to 
experimentally induced resistance to the adverse impact of loss of blood supply. Similar 
paradigm(s) probably occur in human CNS (Alkan, 2009,Busija, et al., 2008,Yuan, et al., 
2004). In the vascular smooth muscle cell within the media layer of arterioles (Fig. 6), the 
KATP channels transmit signals from blood-borne and local factors to modulate blood flow. 
Notably, this cartoon ignores other members of the neurovascular unit such as endothelial 
cells, pericytes, and astrocytes, which express KATP channels also (see below). Finally, in 
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the CNS (Fig. 7), multiple cell types express SUR2 (see below) and the pleitropic effects of 
the gene may include neurotransmitter-responsive excitability (Sun and Hu, 2010). There is 
a recurrent theme of SUR2 proteins sensing Mg++/ADP levels to promote KATP channels’ 
opening and local Ca++ processing; however, the physiologic result varies widely according 
to the microenvironment.
ABCC9 in the brain
Specific KATP channel functions are challenging to define experimentally because of 
complexity at many levels: the variable components in mature KATP channels, different 
splice variants of both SUR proteins, functional changes that may result from altered 
intracellular trafficking, post-translational modifications, and the idiosyncrasies of channel 
functions from cell type to cell type. A recent review listed over 50 different K+ channel 
proteins in the mammalian CNS, and acknowledged formidable “challenges presented by 
the combined molecular complexity of [K+ channels] and structural complexity of the 
mammalian brain” (Trimmer, 2015). That review article focused on the pore-forming K+ 
channel proteins so ABCC9/SUR2 was not mentioned. As stated above, KATP channels may 
be composed of mixtures of regulatory (SUR1/SUR2) and pore-forming (Kir6.1/Kir6.2) 
subunits (Wheeler, et al., 2008,Yoshida, et al., 2004) and each combination has different 
attributes (Cheng, et al., 2008,Yamada, et al., 1997) although there may be constraints on the 
combinatorial potential of an individual channel complex (Giblin, et al., 2002). A discussion 
of some of the characteristics of the various KATP channel assemblages is presented 
elsewhere (Babenko, et al., 1998). Relatively little is known about the gene regulatory 
orchestration of the biologically integrated channel components in brain. Interestingly, the 
human SUR2 3’UTR is variable in length (al) which may be a pathway for regulating 
transcript stability (Nelson and Keller, 2007). Further, mouse Sur1 and Sur2 expression can 
be regulated through promoter DNA methylation (Fatima, et al., 2012).
A fundamental question is -- which cells express the mRNA and proteins? In brief, SUR2 is 
likely expressed in every cell type of the human brain, including neurons, astrocytes, 
oligodendrocytes, ependymal cells, microglia, pericytes, vascular smooth muscle, and 
endothelial cells. It is a common overgeneralization that SUR2A is a skeletal and cardiac 
muscle protein whereas SUR2B is a vascular smooth muscle protein -- the actual expression 
pattern of SUR2 isoforms is less straightforward. One of the technical limitations to the 
study of ABCC9/SUR2 is the lack of “gold-standard” molecular probes that could 
characterize comprehensively the subtypes of ABCC9-derived transcripts and polypeptides 
that are expressed. From the perspective of lab bench researchers that have assessed the 
results of multiple SUR2 antibodies, we can attest to the imperfect apparent specificity of 
some of these probes in our hands (see Ref. (Nelson, et al., 2014)). Prior studies of SUR2 
gene expression focused on non-human mammals. Zhou et al (Zhou, et al., 2012) studied 
SUR2 distribution (mRNA and protein) in rat brain and found widespread expression; 
neurons predominantly expressed SUR2A whereas SUR2B was more expressed in glial 
cells. Interestingly, arteries from different anatomical areas of pig brains also were reported 
to show distinctive profiles of SUR2A and SUR2B expression (Jansen-Olesen, et al., 
2005,Ploug, et al., 2006,Ploug, et al., 2008). Probes that were not isoform-specific 
demonstrated SUR2 protein in rat dorsal root ganglia neurons (Zoga, et al., 2010), and, a 
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study of hippocampal neurons using single-cell PCR showed that SUR2 expression was 
more common among hippocampal interneurons than pyramidal-type excitatory neurons 
(Zawar, et al., 1999). Experiments in cultured primary rat neurons also found substantial 
SUR2 expression (Ma, et al., 2009). A different study of rats showed that neuronal SUR2 
expression (both mRNA and protein level) increased following neurotoxin lesions in the 
prefrontal cortex (S. Wang, et al., 2005).
Looking beyond anatomical and cellular distribution patterns, assessment of the functional 
roles of ABCC9/SUR2 in the mammalian brain is also confounded by the imperfect 
specificity of many of the experimental approaches. For example, most of the drugs that 
impact SUR2, including glibenclamide, also affect SUR1. Many prior studies– in the 
substantia nigra, in the hypothalamus, and elsewhere have focused on SUR1. Single cell RT-
PCR indicates that the KATP channels in those cells are probably comprised primarily of 
SUR1 and Kir6.2 (Hicks, et al., 1994,Lee, et al., 2011,Liss, et al., 1999,Wu, et al., 1996), but 
over-reliance on the sulfonylurea marker [3H-Glibenclamide] may detect SUR2 as well as 
SUR1, and genetic manipulations in rodents have focused on the Kir6.x genes, which do not 
distinguish between Sur1 or Sur2 partner proteins.
Although there is evidence to indicate ABCC9/SUR2-related mechanisms are important for 
neuron (Ma, et al., 2008,Ma, et al., 2009,Tanner, et al., 2011,Xie, et al., 2010,Zawar, et al., 
1999), astrocyte (Wang, et al., 2014,Zhou, et al., 2012,Zhu, et al., 2008), and 
oligodendrocyte (Fogal, et al., 2010) function, there are presently more bases for a 
discussion of the published literature regarding the impact of ABCC9/SUR2 on brain 
vasoregulation. SUR2 may contribute in multiple ways to the complicated task of regulating 
CNS blood flow and neuroinflammation. In particular, KATP channels have been shown to 
play important roles in vascular smooth muscle cells (Ko, et al., 2008,Nichols, et al., 
2013,Shi, et al., 2012,Standen and Quayle, 1998,Sun and Hu, 2010) including primary 
effects of vasoactive diffusible factors (nitric oxide and hydrogen sulfide) (Liang, et al., 
2011,Shi, et al., 2012,Wang, et al., 2014). SUR2-containing KATP channels are biochemical 
substrates partly responsible for vasodilation following oxygen and/or glucose deprivation 
(Adebiyi, et al., 2011). There have been relatively few study of brain arterioles in 
association with genetic or pharmacologic manipulations of SUR2 per se. However, smooth 
muscle cells are not the only cell type of the neurovascular unit that express ABCC9; for 
example, SUR2B was identified as upregulated in rat capillaries of stroke-prone 
spontaneously hypertensive rats and hypothesized to contribute to their endothelial 
dysfunction (Kirsch, et al., 2001). Further, in mouse embryo brains, ABCC9 is robustly 
expressed in the pericytes (Bondjers, et al., 2006). Finally, there are multiple lines of 
evidence that KATP channels help regulate inflammatory signaling in microglia. SUR2B 
may modulate the microglial release of pro-inflammatory factors including TNF-alpha and 
reactive oxygen species (Sun and Hu, 2010). Microglia appear to activate a microglial-
>neuronal precursor mechanism that includes KATP channel activation (Ortega, et al., 
2012,F. Zhou, et al., 2008). However, many of the above studies are confounded by both 
technical and theoretical complexities that render an “overview” challenging.
A perspective on prior discoveries related to ABCC9/SUR2 in the brain, along with insights 
into therapeutic potential, may be conveyed through a cross-section of the reports that 
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focused on a particular drug candidate molecule, iptakalim (systematic name: 2, 3–dimethyl-
N-[1-methylethyl]-2-butanamine). Iptakalim is an “atypical KATP channel opener” agent 
that is administered orally and penetrates the blood-brain barrier, with pharmacologic 
activation of KATP channels that varies by SUR protein types: SUR2B>SUR2A>>SUR1 
(Costa, 2009,Gao, et al., 2005,Sikka, et al., 2012). Iptakalim has been shown to exert effects 
that hint at the potential for clinical benefits. The drug is neuroprotective in experimental 
models of stroke and Parkinson’s disease (Hu, et al., 2005,H. Wang, et al., 2005a,H. Wang, 
et al., 2005b,Wang, et al., 2004,S. Wang, et al., 2005,Wang, et al., 2006,Yang, et al., 
2004,Yang, et al., 2005,Yang, et al., 2009,Zhang, et al., 2011,Zhou, et al., 2007). Other 
experimental results reported for iptakalim in mammals include beneficial neurochemical 
effects that may help to combat depression or psychoses (Lu, et al., 2014,Volf, et al., 2012). 
Preliminary clinical trials have indicated lack of adverse side effects in human research 
volunteers (Cai, et al., 2012,Duan, et al., 2011). Much remains to be learned about the 
potential therapeutic and/or side effects of iptakalim.
ABCC9 gene variants in human diseases: overview
For iptakalim or any drug, exhaustive biologic characterization is not a necessary 
prerequisite to developing a therapeutic strategy. There are many examples of drugs whose 
safety and efficacy were determined prior to full insights into drug mechanism(s). This may 
be kept in mind as we shift topics, from the incompletely understood ABCC9 mechanisms of 
action, and toward a description of human diseases that are linked to the gene.
Multiple ABCC9 allelic variants are associated with human diseases. A genetic disease 
condition called hypertrichotic osteochondrodysplasia, or Cantu syndrome (Harakalova, et 
al., 2012,van Bon, et al., 2012), is caused by heterozygous ABCC9 mutations that so far are 
clustered in the exons encoding the core of SUR2 (Czeschik, et al., 2013,Harakalova, et al., 
2012,van Bon, et al., 2012) and therefore will be expressed in SUR2A and SUR2B (Grange, 
et al., 2014,Nichols, et al., 2013). Cantu syndrome is rare with <100 cases reported to date 
(Scurr, et al., 2011) (see below). The clinical features include disorders of bones, heart, and 
hair follicles (hirsuitism) with macrocephaly often observed (Cantu, et al., 1982,Nevin, et 
al., 1996). Whereas the reasons for the manifestations are not known, the mechanism for 
Cantu syndrome is gene gain-of-function, reducing the sensitivity of channel activation to 
the ADP/ATP ratio (Nichols, et al., 2013). While ABCC8 or KCNJ8 gene deletion in mice 
results in a Prinzmetal angina-like phenotype with elevated blood pressures (Chutkow, et al., 
2002,Li, et al., 2013,Miki, et al., 2002), no specific human monogenic syndrome has yet 
been definitively linked to loss-of-function mutations in ABCC9.
Of direct relevance to the current review, prior published reports all lack neuropathologic 
workup, but underscore that this disease often includes neurological complications, with a 
cerebrovascular component documented in some cases (Table 1). Different reports have 
noted the presence of “mild” mental retardation, autism, intellectual disability, and/ or 
neuroimaging-based brain abnormalities – at least one of these conditions was noticed in 
28/47 (60%) of Cantu syndrome cases described to date (Table 1). The neurologic 
developmental delay that can be seen in Cantu syndrome may be partly secondary to skeletal 
muscle manifestations, i.e. hypotonia (Grange, et al., 2014) or may be related to alterations 
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in brain blood flow. Importantly, two mutations in KCNJ8/Kir6.1 which also result in gain-
of-function in expressed KATP channels, are associated with Cantu syndrome, along with 
neurological phenotype with tortuous cerebral blood vessels (Brownstein, et al., 
2013,Cooper, et al., 2014).
Whereas Cantu syncrome is a congenital defect that may have pleitropic manifestations, a 
number of exonic ABCC9 variants have been associated with cardiovascular diseases 
including atrial fibrillation, vasospasm, dilated cardiomyopathy, and myocardial infarction 
(Barajas-Martinez, et al., 2012,Beziau, et al., 2014,Bienengraeber, et al., 2004,Kane, et al., 
2005,Nichols, et al., 2013,Olson, et al., 2007,Smith, et al., 2013); Table 2. Variants in 
ABCC9 have also been reported in association with Brugada (cardiovascular) syndrome and 
early repolarization syndrome (Barajas-Martinez, et al., 2012,Hu, et al., 2014). In prior 
studies, as with Cantu syndrome cases, there has not been systematic neuropathological nor 
neuroimaging-based assessment of blood vessels to date in the brains of patients with 
disease-associated exonic ABCC9 polymorphisms.
In contrast to the results of ABCC9 exonic mutations, intronic single nucleotide 
polymorphisms (SNPs) have been linked to diverse non-cardiac clinical phenotypes (Table 
2). Some genetic associations were reported that are intriguing but did not identify a single 
particular SNP that met criteria for a statistically significant association with a specific 
disease. For example, ABCC9 SNPs were associated with Hirschprung disease (most 
significant SNP was rs704192) in a genomewide association study (GWAS) of 123 persons 
with “sporadic” Hirschprung disease, and 432 unaffected controls (Kim, et al., 2014). In a 
separate GWAS with 281 elderly individuals, a SNP (rs10743430) was associated with 
entorhinal cortical thinning on magnetic resonance imaging (MRI) (Furney, et al., 2011). 
Further, 2 reports linked ABCC9 polymorphism with hypertension. Sato et al (Sato, et al., 
2006) identified a combination of SNPs that correlate with essential hypertension in a cohort 
of 405 individuals, and Kamide et al (Kamide, et al., 2013) found in a cohort of 265 persons 
that an ABCC9 SNP is associated with responses to anti-hypertension drugs.
In terms of genomic studies that reported statistically significant associations between 
ABCC9 SNPs and human illnesses, these conditions have tended to be brain disorders: sleep 
problems, depression, and HS-Aging. These SNPs are best considered “risk factors” because 
the allelic variant shows far lower genetic penetrance than the exonic mutations. The sleep 
and depression studies come from two separate research groups and the results incompletely 
overlap. Allebrandt et al (Allebrandt, et al., 2013) found that there is an ABCC9 SNP 
(rs11046205) associated with sleep duration. A follow-up study by Parsons et al (Parsons, et 
al., 2013) failed to replicate the primary SNP association but identified a rare polymorphism 
nearby (rs11046209) that was associated with altered sleep duration and found that 
rs11046205 status was associated in that sample with depressive symptoms (Parsons, et al., 
2013).
ABCC9 in hippocampal sclerosis of aging (HS-Aging)
The association between ABCC9 genetic polymorphism and HS-Aging suggest a 
pathogenetic mechanism with substantial impact on public health. HS-Aging is prevalent 
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among aged individuals, affecting up to 25% of the “oldest-old” (Kuslansky, et al., 
2004,Leverenz and Lipton, 2008,Murray, et al., 2014,Zarow, et al., 2008,Zarow, et al., 
2012). HS-Aging mimics AD clinically (Brenowitz, et al., 2014,Nag, et al., 2015,Pao, et al., 
2011), and the association between HS-Aging pathology and antemortem cognitive 
impairment is strong, factoring in all other known pathologies (Nag, et al., 2015,Nelson, et 
al., 2010). Importantly, HS-Aging tends to occur in individuals older than 85 years of age at 
death (Dickson, et al., 1994,Murray, et al., 2014,Nelson, et al., 2011,Nelson, et al., 2013).
The neuropathology of HS-Aging is characterized by cell loss and astrocytosis in the 
hippocampal formation of aged persons that is out of proportion to the Alzheimer’s-type 
plaques and tangles (Montine, et al., 2012). Focusing on the pathology-based 
endophenotype, we performed a GWAS and replication experiment that incorporated 363 
HS-Aging cases and 2303 controls, from 5 separate large autopsy cohorts, with every case 
pathologically evaluated (Nelson, et al., 2014). This study yielded only a single statistically 
significant risk locus for HS-Aging, an ABCC9 SNP pair (rs704178 and rs704180) that are 
co-inherited. Subsequently, we performed an additional replication assessment of a separate 
group of individuals with 51 HS-Aging cases and 561 controls (again, all cases were 
pathologically verified) that replicated the association between rs704180 risk genotype and 
HS-Aging pathology (Nelson, et al., 2015). Interestingly, there appears to be genetic 
“hotspot” with common SNPs associated with HS-Aging pathology and other disease 
phenotypes. For example, the SNP associated with Hirschprung disease (Kim, et al., 2014) 
-- rs704192 -- is in relatively close linkage disequilibrium to rs704180 (r2=0.55, D’ statistic 
~0.91). The SNP associated with both sleep duration and depression (Allebrandt, et al., 
2013,Parsons, et al., 2013) -- rs11046205 -- is in the same intron as rs704178, <2000 bases 
away. We also note that the SNP (rs10743430) that showed association (Furney, et al., 
2011) with entorhinal cortical thinning (P~1e-7 but not genomewide significant) is not 
within the ABCC9 gene itself, but upstream and intergenic. However, evaluation of public 
access databases indicate that rs10743430 may be an expression quantitative trait locus for 
ABCC9 (data not shown).
Prospects for development of therapeutic strategies may be enhanced by better 
understanding disease mechanisms. A key challenge is determining which disease paradigm 
best fits for HS-Aging: is it a neurodegenerative disease, or a cerebrovascular disease? 
Cerebrovascular diseases are characterized by disrupted blood supply, with relatively 
unpredictable clinical and anatomic disease progression. By contrast, neurodegenerative 
diseases usually follow a progressive clinical course, with pathognomonic “inclusion 
bodies” within specific brain areas.
Although the pathogenesis of HS-Aging is incompletely understood, some published 
findings suggest vascular factors cause or exacerbate the disease. Dickson et al (Dickson, et 
al., 1994), in a seminal study of 13 aged individuals with hippocampal sclerosis, observed 
severe “arteriosclerosis” in 12 of the 13 cases, after which others (Reed, et al., 2007,White, 
et al., 2002,Zarow, et al., 2008) also hypothesized a link between hippocampal sclerosis and 
cardiovascular risk factors. Subsequent studies have provided a more specific focus. We 
performed a systematic analysis of multiple large autopsy series and found that among 
vascular pathologies in the brain, only arteriolosclerosis – dysmorphic changes in small 
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arterioles (Fig. 8) – is associated with HS-Aging pathology (Neltner, et al., 2014). In HS-
Aging cases, arteriolosclerosis was observed in regions outside of the hippocampal 
formation, indicating a “whole-brain disease” rather than a disease process isolated to the 
medial temporal lobe. Intriguingly, Montagne and colleagues recently showed that subtle 
blood-brain barrier dysfunction and “leaky vessels” in the human hippocampus precede 
cognitive impairment in advanced aging (Montagne, et al., 2015). Winkler et al (Sagare, et 
al., 2013) reported that pericyte damage could contribute to cognitive impairment through 
disruption of the neurovascular unit, which may relate to HS-Aging rather than AD. ABCC9 
has also been shown to be expressed in pericytes and its impairment associated with leaky 
vessels (Bondjers, et al., 2006), and KATP channels have been shown to be sensitive to 
cerebral ischemia (Armstead, 1997,Lindauer, et al., 2003,Sun and Hu, 2010).
Alongside the findings linking HS-Aging to cerebrovascular disease, brains of patients with 
HS-Aging pathology have pathologic features that are indicative of a neurodegenerative 
condition. A key pathologic biomarker for HS-Aging is aberrant TDP-43 inclusion bodies 
that may resemble the staining pattern of hippocampal TDP-43 pathology observed in 
frontotemporal lobar degeneration (FTLD), a neurodegenerative disease (Amador-Ortiz, et 
al., 2007a,Amador-Ortiz, et al., 2007b,Aoki, et al., 2015,Neumann, et al., 2006). Further, 
some gene variants (in or near GRN and TMEM106B genes) that are associated with 
increased risk for HS-Aging (Dickson, et al., 2010,Murray, et al., 2014,Nelson, et al., 
2015,Pao, et al., 2011,Rademakers, et al., 2008) were previously associated with increased 
risk for FTLD (Deming and Cruchaga, 2014,Van Deerlin, et al., 2007). The clinical course 
of HS-Aging also tends to follow the trajectory of a neurodegenerative disease (Nelson, et 
al., 2011).
So how could HS-Aging be related to both cerebrovascular disease and neurodegenerative 
disease? The ABCC9 genetic association may be a critical clue to help solve the riddle. 
Although there are valid reasons to contradistinguish neurodegenerative and cerebrovascular 
disorders, there is increasing evidence in support of a more nuanced paradigm with “mixed” 
pathogenetic mechanisms in the aged human brain (Montine, et al., 2014,Snyder, et al., 
2014,Weller, et al., 2015). TDP-43 pathology is not specific for neurodegenerative diseases, 
having been reported in a wide variety of brain disorders including Alexander’s disease, 
Down syndrome, low-grade glial neoplasms, and chronic brain trauma (Davidson, et al., 
2011,Lee, et al., 2008,Ling, et al., 2013,McKee, et al., 2010,Walker, et al., 2014), so there is 
overlap between pathologic findings that are seen in “reactive” and “neurodegenerative” 
conditions. Note that in each of the above conditions there is a brain injury or disease that 
occurs over a long time period, as opposed to an acute condition. It is quite possible that a 
subtype of chronic vascular insult(s) could induce TDP-43 phosphorylation and misfolding, 
although acute anoxic or hypoxic changes lack TDP-43 pathology (Amador-Ortiz, et al., 
2007b,Lee, et al., 2008,Nelson, et al., 2011,Zarow, et al., 2008). Conversely, many vascular 
abnormalities have been described in AD brains (Brown and Thore, 2011,Farkas and Luiten, 
2001,Hamel, 2014,Hunter, et al., 2012,Kalaria, et al., 2012). The established functions of 
human ABCC9/SUR2 include both regulating arteriolar smooth muscle tone and 
participating in pathways that have been implicated in neurodegenerative diseases, e.g., 
hypoxia/ischemia, neuroinflammation, and injury responses. There are also published 
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studies that support direct connections between ABCC9/SUR2 and neurodegenerative 
diseases, including both HS-Aging and AD. For example, in a study of Abcc9 knockout 
mice, the biological pathway most affected (versus wildtype) was “Alzheimer’s disease” 
(Gao, et al., 2014). Moreover, treatment of mice that model Alzheimer’s-type pathology 
with SUR2 activators causes attenuation of pathology (Goodman and Mattson, 
1996,Heurteaux, et al., 1993,Kong and Ba, 2012,Liu, et al., 2002,Liu, et al., 2010,Liu, et al., 
2003). There is as yet unclear understandings of the cross-talk between the normal and 
disease pathways. A very recent paper found direct evidence for KATP channels regulating 
brain Aβ peptide release, and concluded that “the identification of these channels as a link 
between hyperglycemia and AD pathology creates an avenue for translational research in 
AD.” (Macauley, et al., 2015)
Data from multiple sources are thus compatible with the novel hypothesis that long-term 
ABCC9 dysregulation due to a genetic variant may manifest, in the “oldest-old”, in a 
pathologic phenotype that combines features of a cerebrovascular disease (arteriolosclerosis) 
and a neurodegenerative disease (hippocampal TDP-43 pathology and cell loss). The KATP 
channels may also be directly relevant to AD pathology. The details of a stereotypical 
timeline or causal hierarchy of mechanisms are as yet beyond our grasp but Fig. 8 conveys 
one plausible hypothesis, and a credible molecular pathway for disease modification.
Going forward: prospects for neurotherapeutic strategies
ABCC9/SUR2 is an attractive candidate for therapeutic strategies because it is well-
established as a “druggable target”. Pharmacological agents that modify SUR function are 
well known and prescribed widely around the world. Both agonists (nicorandil, diazoxide, 
iptakalim) and antagonists (sulfonylurea drugs) have been applied in clinical trials. In 
addition to treatment of monogenic diseases such as Cantu syndrome, such drugs may be 
repurposed for other human pathologies including cardiovascular diseases, as well as sleep 
disorders and depression. Currently we have no perfect animal model for HS-Aging to study 
with these well-characterized drugs. This is an area of active research in our laboratory. An 
important point about characterized drugs that affect SUR2 function is that each has 
different specificity for SUR2A, SUR2B, and SUR1, and each could exert different impact 
on the brain due to blood-brain barrier penetration and other factors (for example, the 
sulfonylurea drugs tend to be water-insoluble (Davis, et al., 1982,Miralles, et al., 1982)). 
The overall impact on an organism and/or disease progression is therefore stochastic and 
more work may be required to engineer drugs tailored to specific targets, and applicable to 
particular brain functions or diseases.
In summary, the ABCC9 gene, and its polypeptide SUR2 product, occupies an intriguing 
biological niche relevant to stress response and vasoregulation in the brain. The direct 
implications for human diseases are most sharply defined for Cantu syndrome, characterized 
by subtle but intriguing neurological manifestations. Potentially more important in terms of 
human disease prevalence are the associations between ABCC9 and sleep disorders, 
depression, and HS-Aging. For now, more understanding of the biology of ABCC9/SUR2 
and KATP channels in the human brain is required. Better resources for manipulation and 
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assay of KATP channel subcomponents are also needed, in order to realize the potential for 
positive impact on public health through greater focus on this pathogenetic gene.
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• ABCC9 encodes SUR2, a metabolic sensor protein that has been shown to 
change (expression and function) in aging
• ABCC9 is also strongly implicated in vasoregulation
• ABCC9 has been implicated in neurologic diseases including sleep, depression, 
and hippocampal sclerosis of aging (HS-Aging)
• HS-Aging is a prevalent and impactful brain disease of advanced old age
• ABCC9/SUR2 is a potentially druggable target that may provide a future 
therapeutic strategy
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Figure 1. Schematic representation of the genes and proteins that make up the human KATP 
channel
A. The ABCC9 gene resides on chromosome 12p and encodes the SUR2 protein. 
Approximately 20 kilobases 3’ from ABCC9 is the KCNJ8 gene that encodes for the Kir6.1 
protein. Paralogous genes on chromosome 11p are ABCC8, which encodes for SUR1 
protein, and KCNJ11 which encodes for Kir6.2 protein. B. Studies on crystal structure have 
elucidated how the KATP channel is organized in the plasma membrane. The KATP channel 
constitutes a hetero-octamer that includes combinations of 4 SUR1/SUR2 proteins, and 4 
Kir6.1/Kir6.2 proteins, with the Kir6.x proteins forming the channel pore. C. When the 
KATP channel is functionally working in the plasma membrane, it allows K+ ions out and is 
responsive to ATP/ADP ratio and pharmacological agonists (e.g., nicorandil and diazoxide) 
and antagonists (sulfonylurea drugs).
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Figure 2. Protein structure of human ABCC9 encoded SUR2 polypeptides
These are relatively large proteins (~150kDa) with multiple membrane-spanning domains. 
Like all ABCC gene-encoded proteins, SUR2 has two transmembrane (“TMD”) domains, 
along with two nucleotide-binding (“NBD”) domains. A characteristic feature of the 
sulfonylurea subcategory of ABCC genes is the presence of a third transmembrane domain, 
TM0. SUR2 has a specialized element in the extreme carboxy end, where two alternatively 
spliced exons lead to two variants (SUR2A and SUR2B) according to that portion. B. A 
variant of SUR2 has been described in mitochondria (~55kDa), shortened as a result of 
alternative splicing as shown.
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Figure 3. Phylogenetic tree provides background on evolution and protein-level identity with 
paralogous proteins
Shown is the result of a phylogenetic tree generated by comparing the protein-level 
sequences of ABCC proteins using the Web-based alignment tool (http://
blast.ncbi.nlm.nih.gov/blast). Also shown for each species/gene in the tree is the protein 
level percent identity for human full-length SUR1/SUR2A/SUR2B proteins. Each of these 
genes is relatively well-conserved in vertebrate species. Further, there are invertebrate 
orthologs (shown are SUR protein data related to fruit flies and mosquitos) that appear more 
homologous to human SUR2 than to SUR1 proteins. For comparison, a presumed ortholog 
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is included in the phylogenetic tree: the human ABCC gene CFTR/ABC7. This is the gene 
responsible for the most common lethal human genetic disease, cystic fibrosis (Riordan, et 
al., 1989).
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Figure 4. Alternative splicing in humans is complex, leading to multiple variants of SUR2 
transcripts and proteins(Shi, et al., 2005)
A. Basic genomic structure of ABCC9 includes at least 39 potential exons, not including 
untranslated regions (UTRs). B. Transcript designated “SUR2B” (ENST00000261200) 
includes Exon 39 but not Exon 38. This transcript incorporates 3’ UTR regions of varying 
lengths which may affect transcript(s) stability. C. Transcript designated “SUR2A” 
(ENST0000026120) includes Exon 38 but not Exon 39 and was recently described to have 
an unique 3’UTR from genomic sequence immediately downstream from Exon 38 (al). D. A 
separate transcript, designated “SUR2Ab” (not yet annotated) incorporates both Exon 38 
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and Exon 39; whereas this transcript is translated similar to “SUR2A”, it harbors the 3’UTR 
that is associated with SUR2B transcript (al). E. Human SUR2A- and SUR2B–like clones 
have been characterized that do not include Exon 17 (NM_005691 and NM_020297) 
(Davis-Taber, et al., 2000). F. Human SUR2A–like clones were characterized that do not 
include Exon 14 (NM_020298). G. Transcripts that produce SUR2-like proteins in 
mitochondrial lack a large portion (from Exons 4–29) but may incorporate either Exon 38 or 
Exon 39 (Ye, et al., 2009). Transcripts that have been annotated, but not functionally 
characterized, which include exons exclusively from either the 5’ portion (H) or the 3’ 
portion (I) of the ABCC9 gene (ENST00000544039,ENST00000538350, and 
ENST00000326684).
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Figure 5. Mechanistic progression associated with SUR2 in a generic cell-type
1. Stressors and/or hypoxia lead to decreased intracellular ATP/ADP ratio. 2. At the plasma 
membrane, the ATP/ADP ratio, as well as other messengers not shown, can shift the KATP 
channel from a closed to open configuration, leading to K+ ions leaving the cell. 3. The K+ 
ions alter (reduce) the membrane depolarization leading to shift in the voltage-gated Ca++ 
pump dynamics. 4. In mitochondria, overlapping signals can affect the local mitochondria 
and mitochondrial SUR2, which is currently imperfectly understood but which also can alter 
mitochondrial Ca++ processing and energy production. 5. A key net outcome of SUR2 
function and KATP channel opening is to decrease local intracellular Ca++ levels which can 
buffer the impact of the stress/hypoxic challenge.
Nelson et al. Page 35









Figure 6. SUR2 and KATP channels play key roles regulating arteriolar function including 
vasodilation (1–5) and vasoconstriction (6–8)
1. Blood-borne vasodilatory agents (adenosine, nitric oxide, and others) can function 
through either membrane receptors (e.g., adenoside) or by diffusible (nitric oxide) 
mechanisms. 2. Intracellular second messengers including protein kinase A (PKA) can 
phosphorylate SUR2 and promote KATP channel opening. 3. It is not well understood how 
local brain ischemia/hypoxia, or local neuronal excitability, may also promote KATP channel 
opening in vivo. 4. The KATP channel promotes decreased intracellular Ca++, vasodilation, 
and increased local blood flow. 5. By contrast, other signals can promote vasoconstriction, 
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including norepinephrine. 6. One pathway to promote smooth muscle contraction through 
KATP channel mechanism is the PKCe. 7. Other brain-specific pathways including neuronal 
signaling may also lead to KATP channel closing. 8. The net effect of KATP channel closing 
is to increase intracellular Ca++, contract smooth muscle in the tunica media of arterioles, 
and decrease local blood flow. This figure incorporates information from recent reviews 
(Flagg, et al., 2010,Ko, et al., 2008). Here we show cartoon depiction of the KATP channel in 
smooth muscle cells but it should be kept in mind that KATP channels have also been shown 
to affect endothelial cells, pericytes, and possibly perivascular astrocytes.
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Figure 7. KATP channels have been described in just about every cell type of the human brain
The interplay of KATP channels, alongside the many other subtypes of K+ channels, in the 
human brain is extremely complex. These channels play important roles in regulating 
neuronal excitability, stress response, neuroinflammation, and blood flow. Thus these KATP 
channels are candidates for involvement in human brain diseases when they are 
dysfunctional. Increasing evidence is accumulating to highlight the brain conditions where 
KATP channel may be relevant.
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Figure 8. A polymorphism in ABCC9 showed genome-wide statistically significant association 
with hippocampal sclerosis of aging (HS-Aging) as a GWAS endophenotype (Haug, et al., 
2015,Nelson, et al., 2014)
HS-Aging is a prevalent neurodegenerative condition affecting the “oldest-old” and 
characterized by cell loss and atrophy in the hippocampal formation not due to Alzheimer’s 
disease-type pathways. Another factor associated with HS-Aging pathology is 
arteriolosclerosis, a pathological change where normal arterioles become dysmorphic (as 
shown in the Figure). Whether and how these observations are connected currently is 
unknown. Given the known expression of ABCC9 in vascular smooth muscle cells, a 
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parsimonious hypothesis is that long-term ABCC9 dysregulation may contribute to brain 
arteriolar injury (arteriolosclerosis) which in turns potentiates the manifestation of HS-
Aging pathology. Scale bars = 1mm for A, B. 100 microns for C, D.
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Table 1
Cantu syndrome cases reported to date, with (n=28) and without (n=19) documented neurological conditions
Paper # Cases Notable human CNS findings (Ref)
Cantu et al, 1982 2 1/2 with mild mental retardation/delay (Cantu, et al., 1982)
Nevin et al, 1996 1 Developmentally normal boy (Nevin, et al., 1996)
D. García-Cruz et al, 1997 4
“Mild mental retardation” in 3/4, “enlarged posterior 
fossa” in 4/4. (Garcia-Cruz, et al., 1997)
Rosser et al, 1998 3 Developmental delay noted in 2/3 cases (Rosser, et al., 1998)
S.P. Robertson et al, 1999 2
Developmental delay/mild mental retardation in both 
cases (Robertson, et al., 1999)
D Concolino et al, 2000 1 “Psychomotor development was normal” (Concolino, et al., 2000)
B Lazalde et al, 2000 4 No specific mention of neurological disorders (Lazalde, et al., 2000)
H. Engels et al, 2002 1
Brain atrophy and ultrasound- confirmed “bilateral 
calcification of the Arteriae thalamostriatae” (Engels, et al., 2002)
D.K. Grange et al, 2006
Woman and two 
daughters No mention of cognitive or cerebral anomaly (Grange, et al., 2006)
C. Graziado et al, 2010 1 “mildly delayed psychomotor development” (Graziadio, et al., 2011)
I. Scurr et al, 2010 9 Motor or speech delay in 9/10 cases (Scurr, et al., 2011)
Kobayashi et al, 2010 1 Clinical syndrome included “developmental delay” (Kobayashi, et al., 2010)
J.C. Czeschik et al, 2012 2
Both with ABCC9 mutations, 1/2 with mild 
developmental delay (Czeschik, et al., 2013)
C.L. Garcia-Gonzalez et al, 
2012 1
Delayed psychomotor development with cerebral cortical 
atrophy on CT scan
(Garcia-Gonzalez, et al., 
2012)






All with ABCC9 mutations, 3 diagnosed with intellectual 
disability and/or developmental delay, 8/9 with 
macrocephaly (van Bon, et al., 2012)
Y. Hiraki et al, 2013 Father and son
“mild psychomotor delay … and an autistic disorder 
based on the DSM-IV” (Hiraki, et al., 2014)
J.Y. Park et al, 2014 1
ABCC9 mutation (p.Ala1462Gly, c.4385C>G) 
confirmed; atrophic changes of the brain on MRI (Park, et al., 2014)









Nelson et al. Page 42
Table 2






Cantu syndrome E, I
Apparent autosomal dominant inheritance of functional 
gain of toxic function; many mutations identified, mostly 
in exons coding transmembrane domains of SUR2 protein
(Harak alova, et al., 2012, 
van Bon, et al., 2012)
Atrial fibrillation E Case of mutation [Thr1547Ile] associated with atrial fibrillation originating in the vein of Marshal (Olson, et al., 2007)
Dilated cardiomyopathy E Two cases with distinct mutations [frameshift1524, A1513T] associated with dilated cardiomyopathy
(Bienen graeber , et al., 
2004)
Myocardial infarction, early 
repolarization syndrome (ERS), 
and Brugada syndrome (BrS)
E
Coronary arterial vasospam and myocardial infarction 
linked to V734I mutation. Severe cardiac arrhythmias 
associated with 8 ABCC9 mutations from 11 BrS probands 
and 4 ERS probands, the latter with V734I mutations.
(Baraja s-Martine z, et al., 
2012, Beziau, et al., 2014, 
Hu, et al., 2014, Minoretti, et 
al., 2006, Smith, et al., 2013)
Sleep disorder I
ABCC9 SNP rs11046205 and rs11046209 showed some 
association with sleep duration, but with some variation 
between studies
(Allebr andt, et al., 2013), 
(Parsons, et al., 2013)
Depression I ABCC9 SNP rs11046205 was associated with depressive 
symptoms (Parsons, et al., 2013)
Hippocampal sclerosis of aging 
(HS-Aging) I
GWAS with genome-wide statistical significance and 
separate replication study show association between HS-
Aging and a group of intronic SNPs that include rs704180
(Nelson, et al., 2014, 
Nelson, et al., 2015)
Blood pressure/hypertension I ABCC9 SNPs were associated with angiotensin II receptor blocker medication response (Kamide, et al., 2013)
Blood pressure/hypertension I A haplotype (ABCC9 SNP combination) is associated with 
risk for essential hypertension (Sato, et al., 2006)
Entorhinal cortex thinning G SNP rs10743430 is ~50,000bases upstream from ABCC9 In GWAS for MRI-detected atrophy; p~6E-7. (Furney, et al., 2011)
Hirschprung disease I Top SNP (rs704192) is in linkage disequilibrium with HS-Aging risk SNPs (Kim, et al., 2014)
*
Exonic (E), Intronic (I), Intergenic (G)
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